Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NOLVADEX vs CLOMIPHENE CITRATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
NOLVADEX (tamoxifen citrate) is a nonsteroidal selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to estrogen receptors in breast tissue, thereby blocking estrogen-mediated cell proliferation. It also has partial agonist activity in other tissues such as bone and endometrium.
Selective estrogen receptor modulator; competes with estrogen for binding at estrogen receptors in the hypothalamus, inhibiting negative feedback and increasing gonadotropin-releasing hormone (Gn RH) secretion, leading to increased LH and FSH release from the pituitary.
Treatment of metastatic breast cancer in women and men,Adjuvant treatment of breast cancer in women with node-positive or node-negative disease following primary surgery,Reduction of breast cancer incidence in high-risk women (pre- and postmenopausal) for primary prevention,Reduction of contralateral breast cancer risk in women with ductal carcinoma in situ (DCIS) or prior breast cancer,Off-label: Induction of ovulation in anovulatory infertility; treatment of gynecomastia; reduction of breast cancer risk in BRCA mutation carriers
Treatment of ovulatory dysfunction in women desiring pregnancy,Off-label: male infertility (oligospermia), induction of ovulation in assisted reproductive technology
20-40 mg orally once daily; for breast cancer, 20 mg/day. For adjuvant therapy, 20 mg/day for 5 years. For ductal carcinoma in situ, 20 mg/day for 5 years. For reduction of breast cancer incidence in high-risk women, 20 mg/day for 5 years.
50 mg orally once daily for 5 days, starting on day 5 of menstrual cycle; may increase to 100 mg orally once daily for 5 days if ovulation not achieved.
Tamoxifen: 5-7 days (terminal). N-desmethyltamoxifen (active metabolite): 14 days. Steady-state achieved in 3-4 weeks.
Terminal elimination half-life is approximately 5–7 days (120–168 hours) for the active zu-isomer, with a longer half-life for its metabolites. This prolonged half-life leads to accumulation with repeated dosing and sustained clinical effects.
Extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2D6 (to active metabolite endoxifen) and CYP3A4, with contributions from CYP2B6, CYP2C9, and CYP2C19. Undergoes glucuronidation and sulfation. Endoxifen is further metabolized by CYP3A4.
Hepatic metabolism; excreted in feces; active metabolites (possibly enterohepatic recirculation).
Primarily fecal (65%) as conjugates; renal excretion accounts for approximately 25% as metabolites and <0.5% as unchanged drug. Biliary elimination contributes 10%.
Primarily fecal (approximately 50%), with about 8% renal excretion of unchanged drug and metabolites. Biliary excretion is significant, with enterohepatic recirculation contributing to prolonged elimination.
>99% bound primarily to albumin.
Approximately 80–90% bound to albumin, with significant binding to other plasma proteins including sex hormone-binding globulin (SHBG).
50-60 L/kg, indicating extensive tissue distribution (e.g., breast, liver, uterus).
Apparent volume of distribution is large, approximately 50–100 L/kg, indicating extensive tissue distribution and accumulation, particularly in the liver and reproductive organs.
Oral: Approximately 100% after first pass due to extensive hepatic metabolism; absolute bioavailability is nearly complete but variable.
Oral: ~100% absorbed, but bioavailability is difficult to quantify due to extensive first-pass metabolism and enterohepatic cycling; essentially complete systemic exposure after oral administration.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <30 m L/min), use with caution; no specific guidelines, consider reduced dose.
No specific dose adjustment guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
Contraindicated in Child-Pugh class C. For Child-Pugh class B, reduce dose by 50% (e.g., 20 mg every other day). For Child-Pugh class A, no adjustment needed.
Contraindicated in patients with liver disease or hepatic dysfunction; no Child-Pugh based adjustments available.
Safety and efficacy not established in pediatric patients for FDA-approved indications. Off-label use for gonadotropin-independent precocious puberty: 20 mg orally once daily (monitor for potential risks).
Not recommended for use in children; safety and efficacy not established.
No specific dose adjustment recommended based on age alone; dosing same as adults. Monitor for increased risk of thromboembolic events, endometrial cancer, and cataracts. Start at lower end of dosing range (20 mg/day) if frail or with comorbidities.
Not indicated for use in elderly patients; no specific dosing recommendations.
WARNING: SERIOUS AND LIFE-THREATENING EVENTS - NOLVADEX has been associated with an increased risk of uterine malignancies (including endometrial cancer and uterine sarcoma), stroke, and pulmonary embolism. These risks increase with duration of therapy and patient age. Use only when benefit outweighs risk. Educate patients about symptoms of these events and seek prompt medical attention.
Should not be used in patients with liver disease or abnormal uterine bleeding of undetermined origin.
Increased risk of endometrial cancer, uterine sarcoma, and other uterine malignancies; perform baseline gynecologic exam and monitor for abnormal bleeding,Increased risk of thromboembolic events (DVT, PE, stroke); avoid in patients with history of thromboembolism,Hepatotoxicity: elevated liver enzymes, hepatitis, and hepatic steatosis; monitor periodic liver function tests,Ocular effects: cataracts, retinopathy; perform periodic eye exams,Hypercalcemia: may occur in patients with bone metastases; monitor serum calcium,Bone density loss: may cause decreased bone mineral density in premenopausal women; consider calcium and vitamin D supplementation,QT prolongation: use caution with other QT-prolonging drugs or electrolyte imbalances,Fetal harm: can cause fetal harm if used during pregnancy; advise women of childbearing age to use effective contraception
Ovarian enlargement/cysts; visual disturbances; multiple pregnancy; ovarian hyperstimulation syndrome; vasomotor symptoms; blurred vision; prolonged use may increase risk of borderline or invasive ovarian tumors.
History of deep vein thrombosis (DVT) or pulmonary embolism (PE),History of cerebral vascular accident (CVA) or transient ischemic attack (TIA),Known hypersensitivity to tamoxifen or any component of the formulation,Pregnancy (avoid use unless potential benefit justifies potential risk to fetus); use in women of childbearing age only with adequate contraception,Concurrent use with warfarin or other coumarin-type anticoagulants (relative contraindication due to increased bleeding risk),Severe hepatic impairment (Child-Pugh class C)
Pregnancy; liver disease or history; abnormal uterine bleeding of undetermined origin; ovarian cyst or enlargement due to polycystic ovary syndrome; hypersensitivity to clomiphene.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4, potentially altering tamoxifen metabolism. Avoid St. John's wort. No other specific dietary restrictions, but maintain a balanced diet. Alcohol should be limited due to increased risk of liver enzyme elevation.
No significant food interactions. Avoid excessive alcohol consumption as it may impair fertility.
Nolvadex (tamoxifen) is classified as FDA Pregnancy Category D. There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience. First trimester exposure is associated with spontaneous abortions, birth defects (including craniofacial, genital, and skeletal anomalies), and fetal death. Second and third trimester exposure may cause fetal harm including pulmonary hypoplasia and growth retardation. Use is contraindicated during pregnancy.
FDA Pregnancy Category X. Clomiphene citrate is contraindicated in pregnancy. First trimester exposure associated with neural tube defects, cleft palate, and syndactyly. Second and third trimester: no data due to contraindication. Risk of multiple gestation (5-12%) increases risks of preterm labor, low birth weight, and congenital anomalies.
Tamoxifen is excreted in human milk. The milk-to-plasma ratio (M/P) is approximately 0.5-0.75. Due to potential serious adverse reactions in nursing infants, including hormonal effects and carcinogenicity, breastfeeding is not recommended during tamoxifen therapy and for at least 3 months after the last dose.
Excreted into breast milk; M/P ratio unknown. Clomiphene may reduce milk production due to anti-estrogenic effects. Because of potential for adverse reactions in nursing infants, women are advised not to breastfeed during treatment.
Tamoxifen is contraindicated in pregnancy; therefore, dose adjustments are not applicable. If pregnancy occurs during therapy, discontinue tamoxifen immediately and manage with alternative therapies. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered hepatic metabolism) may reduce tamoxifen exposure, but no dose adjustments have been studied or recommended due to risk.
No dose adjustments in pregnancy as drug is contraindicated. If pregnancy occurs, discontinue immediately. No pharmacokinetic studies in pregnant women; drug should not be used.
NOLVADEX (tamoxifen) is a selective estrogen receptor modulator (SERM) indicated for the treatment and prevention of breast cancer. Monitor for endometrial hyperplasia and thromboembolic events. Use with caution in patients with history of DVT/PE. CYP2D6 inhibitors (e.g., paroxetine) reduce conversion to active metabolite endoxifen; avoid coadministration. Tamoxifen can cause tumor flare in bone metastases. Discontinue 2-3 months before attempting pregnancy due to long half-life. Regular gynecologic exams and ophthalmologic monitoring recommended.
Monitor ovarian size and estradiol levels to reduce risk of ovarian hyperstimulation syndrome (OHSS). Use only in patients with ovulatory dysfunction; rule out pregnancy before each cycle. Limit to 6 treatment cycles due to increased risk of ovarian cancer with prolonged use.
Take exactly as prescribed; do not skip doses.,Report any unusual vaginal bleeding, pelvic pain, or changes in vision immediately.,Avoid grapefruit juice as it may affect drug levels.,Use effective non-hormonal contraception during therapy and for 2 months after stopping.,Do not take St. John's wort or other herbal supplements without consulting your doctor.,Report leg swelling, chest pain, or shortness of breath promptly.,May cause hot flashes, nausea, or fatigue; these are not reasons to stop without consulting your doctor.,Attend all scheduled gynecologic and eye exams.
Take clomiphene citrate exactly as prescribed, typically for 5 days starting on day 3-5 of menstrual cycle.,Ovulation usually occurs 5-10 days after the last dose; have intercourse every other day during this window.,Common side effects include hot flashes, mood swings, and visual disturbances; report persistent visual changes immediately.,Risk of multiple pregnancy (mainly twins) is increased; discuss with healthcare provider.,Avoid use if pregnant, have liver disease, or have abnormal vaginal bleeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NOLVADEX vs CLOMIPHENE CITRATE, answered by our medical review team.
NOLVADEX is a Selective Estrogen Receptor Modulator that works by NOLVADEX (tamoxifen citrate) is a nonsteroidal selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to estrogen receptors in breast tissue, thereby blocking estrogen-mediated cell proliferation. It also has partial agonist activity in other tissues such as bone and endometrium.. CLOMIPHENE CITRATE is a Selective Estrogen Receptor Modulator (SERM) that works by Selective estrogen receptor modulator; competes with estrogen for binding at estrogen receptors in the hypothalamus, inhibiting negative feedback and increasing gonadotropin-releasing hormone (Gn RH) secretion, leading to increased LH and FSH release from the pituitary.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NOLVADEX and CLOMIPHENE CITRATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NOLVADEX is: 20-40 mg orally once daily; for breast cancer, 20 mg/day. For adjuvant therapy, 20 mg/day for 5 years. For ductal carcinoma in situ, 20 mg/day for 5 years. For reduction of breast cancer incidence in high-risk women, 20 mg/day for 5 years.. The standard adult dose of CLOMIPHENE CITRATE is: 50 mg orally once daily for 5 days, starting on day 5 of menstrual cycle; may increase to 100 mg orally once daily for 5 days if ovulation not achieved.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NOLVADEX and CLOMIPHENE CITRATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NOLVADEX is classified as Category C. Nolvadex (tamoxifen) is classified as FDA Pregnancy Category D. There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing expe. CLOMIPHENE CITRATE is classified as Category A/B. FDA Pregnancy Category X. Clomiphene citrate is contraindicated in pregnancy. First trimester exposure associated with neural tube defects, cleft palate, and syndactyly. Second and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.